IL-6 blockade reverses the abnormal STAT activation of peripheral blood leukocytes from rheumatoid arthritis patients

IL-6 blockade reverses the abnormal STAT activation of peripheral blood leukocytes from rheumatoid arthritis patients

Copyright © 2015 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 158(2015), 2 vom: 18. Juni, Seite 174-82
1. Verfasser: Ortiz, M A (VerfasserIn)
Weitere Verfasser: Diaz-Torné, C, Hernández, M V, Reina, D, de la Fuente, D, Castellví, I, Moya, P, Ruiz, J M, Corominas, H, Zamora, C, Cantó, E, Sanmartí, R, Juarez, C, Vidal, S
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2015
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't IL-6 Leukocytes Rheumatoid arthritis STATs Tocilizumab Antibodies, Monoclonal, Humanized Interleukin-6 Peptides, Cyclic mehr... STAT1 Transcription Factor STAT1 protein, human STAT3 Transcription Factor STAT3 protein, human cyclic citrullinated peptide tocilizumab I031V2H011
LEADER 01000caa a22002652 4500
001 NLM247792896
003 DE-627
005 20250218090209.0
007 cr uuu---uuuuu
008 231224s2015 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2015.03.025  |2 doi 
028 5 2 |a pubmed25n0825.xml 
035 |a (DE-627)NLM247792896 
035 |a (NLM)25847223 
035 |a (PII)S1521-6616(15)00128-X 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Ortiz, M A  |e verfasserin  |4 aut 
245 1 0 |a IL-6 blockade reverses the abnormal STAT activation of peripheral blood leukocytes from rheumatoid arthritis patients 
264 1 |c 2015 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 25.08.2015 
500 |a Date Revised 25.11.2016 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2015 Elsevier Inc. All rights reserved. 
520 |a Considering the interplay of multiple STATs in response to cytokines, we investigated how IL-6 and its blocking affect STAT signaling in rheumatoid arthritis (RA). Leukocytes obtained from RA patients before and after tocilizumab treatment and healthy donors (HDs) were cytokine-stimulated and STAT phosphorylation was analyzed by cytometry. RA patients had significantly fewer pSTAT1+, pSTAT3+, and pSTAT6+ monocytes and pSTAT5+ lymphocytes than HDs. After 24weeks of treatment, percentages of IFNγ-induced pSTAT1+ and IL-10-induced pSTAT3+ monocytes in RA patients increased, reaching levels comparable to HDs. pSTAT1+ and pSTAT3+ cells correlated inversely with RA disease activity index and levels of pSTAT+ cells at baseline were higher in patients with good EULAR response to tocilizumab. IFNγ-induced pSTAT1+ cells correlated inversely with memory T cells and anti-CCP levels. IL-10-induced pSTAT3+ cells correlated with Treg/Teff ratio. Our findings suggest that IL-6 blocking reduces the inflammatory mechanisms through the correction of STAT1 and STAT3 activation status 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a IL-6 
650 4 |a Leukocytes 
650 4 |a Rheumatoid arthritis 
650 4 |a STATs 
650 4 |a Tocilizumab 
650 7 |a Antibodies, Monoclonal, Humanized  |2 NLM 
650 7 |a Interleukin-6  |2 NLM 
650 7 |a Peptides, Cyclic  |2 NLM 
650 7 |a STAT1 Transcription Factor  |2 NLM 
650 7 |a STAT1 protein, human  |2 NLM 
650 7 |a STAT3 Transcription Factor  |2 NLM 
650 7 |a STAT3 protein, human  |2 NLM 
650 7 |a cyclic citrullinated peptide  |2 NLM 
650 7 |a tocilizumab  |2 NLM 
650 7 |a I031V2H011  |2 NLM 
700 1 |a Diaz-Torné, C  |e verfasserin  |4 aut 
700 1 |a Hernández, M V  |e verfasserin  |4 aut 
700 1 |a Reina, D  |e verfasserin  |4 aut 
700 1 |a de la Fuente, D  |e verfasserin  |4 aut 
700 1 |a Castellví, I  |e verfasserin  |4 aut 
700 1 |a Moya, P  |e verfasserin  |4 aut 
700 1 |a Ruiz, J M  |e verfasserin  |4 aut 
700 1 |a Corominas, H  |e verfasserin  |4 aut 
700 1 |a Zamora, C  |e verfasserin  |4 aut 
700 1 |a Cantó, E  |e verfasserin  |4 aut 
700 1 |a Sanmartí, R  |e verfasserin  |4 aut 
700 1 |a Juarez, C  |e verfasserin  |4 aut 
700 1 |a Vidal, S  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 158(2015), 2 vom: 18. Juni, Seite 174-82  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:158  |g year:2015  |g number:2  |g day:18  |g month:06  |g pages:174-82 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2015.03.025  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 158  |j 2015  |e 2  |b 18  |c 06  |h 174-82